News & Investors
News
Lumicell Appoints Brent Palmisano Chief Commercial Officer, Builds Commercial Team
Lumicell, Inc. today announced it is building a commercial team to prepare for market launch of the Lumicell Direct Visualization System (DVS) which includes its novel optical imaging agent LUMISIGHT,
Clinical Data on Lumicell’s Direct Visualization System to Be Presented at International Conference on Surgical Cancer Care
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that clinical data from a 234-patient, multi-center feasibility study of the Lumicell Direct
Lumicell Completes Enrollment in the INSITE Pivotal Trial for Intraoperative Breast Cancer Detection & Removal
In a significant milestone for breast cancer patients and advancement toward submission of its Lumicell Imaging System for regulatory approval, Lumicell has completed enrollment in their Investigation of Novel Surgical
Lumicell Granted Fast Track Designation Approval by the FDA for Breast Cancer Treatment
Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced it has received Fast Track designation with rolling review from the FDA Center for Drug Evaluation and Research
Lumicell Announces Initiation of NIH/NCI Academic-Industry Study of its LUM Imaging System
R01 Award to fund multi-phase randomized study to expand clinical safety and efficacy data of the system in the detection of residual tumor in breast cancer patients receiving neoadjuvant therapies
Lumicell Initiates Pivotal Trial for Breast Cancer Surgical Guidance Solution
Success with In Vivo Examination of Cancerous Tissue via the Lumicell Imaging System During the Pivotal Trial will Propel the Technology Toward FDA Submission Newton, Mass., November 5, 2019 – Lumicell, Inc.,
Lumicell Completes Enrollment of Phase C Feasibility Trial for Breast Cancer Surgical Guidance Solution
Pivotal trial expected to begin by end of 2019 for the Lumicell Imaging System for intraoperative detection and removal of residual cancer in breast-conserving surgery. Newton, Mass., August 19, 2019
Feasibility Study Underway to Assess Lumicell Technology for Removing Ovarian and Peritoneal Cancer Tumors During the First Surgery
Positive Clinical Results in Breast Cancer Trial Shows Promise for Ovarian and Other Cancers Newton, Mass., April 10, 2019 — Lumicell, Inc. today announced that a feasibility study is underway at Massachusetts General
Lumicell Headquarters Expands Into New Boston-Area Office Space
New location offers more space for expansion and designed to inspire innovation of Lumicell technology through further employee collaboration Newton, Mass., Feb. 22, 2019— Lumicell, Inc., an innovation leader in
Events
San Antonio Breast Cancer Symposium®,
December 10-14, 2024
Henry B. Gonzalez Convention Center
Investors
